GLP-1

Plug & Play, the innovation platform, is turning its attention to companion nutrition for people taking GLP-1 weight-loss drugs, framing it as the next growth area for the microbiome and nutrition sector. As uptake of medications like Ozempic and Wegovy grows, attention is shifting to foods and supplements that help patients maintain muscle, gut health and nutrient intake while eating less.

A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.

New research indicates that close to one in six children taking GLP-1 medications, widely used for weight management and diabetes, develop nutritional deficiencies. The finding raises questions about monitoring and dietary support for young patients on these increasingly prescribed drugs, as clinicians weigh the benefits of treatment against risks of inadequate nutrient intake during childhood development.

A health news roundup covers four topics: cychlorphine, a substance drawing attention for potential effects on testosterone levels; possible links between GLP-1 weight-loss and diabetes drugs and vision loss; and an ongoing salmonella outbreak tied to jalapeño peppers. Together the items touch on medication safety, supplement trends and a foodborne illness investigation that health officials are monitoring.

Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being described as changing more than obesity treatment, with new discussion of their effects on mental health. The Atlantic examines how these medications may influence mood, addiction and behavior, suggesting the story of weight loss medicine is expanding into psychiatry and brain science.

Supplement company Smidge has introduced a GLP-1 companion bundle aimed at supporting digestion and nutrient intake for people taking GLP-1 medications, which are known to affect appetite and gut function. The bundle is positioned as a nutritional support product for users of these weight-loss and diabetes drugs.

Supplement brand Smidge has introduced a nutrition bundle combining five supplements into a single daily routine, aimed at people taking GLP-1 weight-loss medications. The concept targets nutritional gaps reported by users of drugs like Ozempic and Wegovy, who often eat less and may miss key nutrients. It reflects a broader wave of products being marketed to the fast-growing GLP-1 user base.

A new wave of obesity medicines is being discussed as the field looks beyond the established GLP-1 drugs semaglutide and tirzepatide. Coverage highlights emerging treatments in development that could expand options for patients and clinicians treating obesity, a category that has drawn enormous attention since GLP-1 therapies reshaped weight-loss care. Details on specific drug candidates remain limited.

A new obesity drug has been described as the most powerful yet after trial participants reportedly lost up to 25% of their body weight. The results, reported by Ars Technica, would surpass figures associated with current GLP-1 medications such as Wegovy and Zepbound, intensifying competition among drugmakers in the fast-growing weight-loss treatment market.